Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

View Full Paper
Ask AI
Bookmark
Share

Authors

STSrinivas K. TantravahiCOClaire OligAHAlexander Hinman

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates efficacy of asciminib and TKI in achieving second TFR in CML patients with implications for treatment strategies.

Key Points

  • To evaluate the efficacy of asciminib-based therapy in patients with CML attempting second treatment free remission.
  • Single arm phase II study design with 47-51 enrolled patients.
  • Patients previously attempted TKI discontinuation and were on TKI prior to relapse.
  • Asciminib combined with imatinib, nilotinib, or dasatinib during a 12-cycle treatment phase.
  • Among 9 enrolled patients, 7 reached the second treatment free remission.
  • 5 out of 7 patients remained in treatment free remission after median 384 days.
  • Common adverse events included diarrhea and fatigue.

Cite This Study

Tantravahi et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3dchttps://doi.org/10.1182/blood-2025-7293
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  2. 2Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results2025 · 13 citations
  3. 3Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results2024 · 55 citations
  4. 4Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.2025
  5. 5Asciminib a new player in treatment of TKI-resistant/intolerant chronic phase chronic myelogenous leukemia2024 · 2 citations